Propanc Biopharma
PPCB
6 hedge funds and large institutions have $48.7K invested in Propanc Biopharma in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
50% more funds holding
Funds holding: 4 → 6 (+2)
0.05% more ownership
Funds ownership: 0.04% → 0.09% (+0.05%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
30% less capital invested
Capital invested by funds: $69.5K → $48.7K (-$20.8K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$43.4K |
| 2 |
Jane Street
New York
|
+$34K |
| 3 |
VF
Virtu Financial
New York
|
+$9.67K |
| 4 |
SCA
Sassicaia Capital Advisers
Jericho,
New York
|
+$3.8K |
| 5 |
MG
Marex Group
London,
|
+$641 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$13.7K |
| 2 |
Two Sigma Investments
New York
|
-$8.72K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$2.38K |
| 4 |
Morgan Stanley
New York
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $19.4K | +$43.4K | +7,305 | New |
|
|
2
Jane Street
New York
| $15.2K | +$34K | +5,728 | New |
|
|
MG
3
Marex Group
London,
| $7.18K | +$641 | +108 | +4% |
|
|
VF
4
Virtu Financial
New York
| $4K | +$9.67K | +1,630 | New |
|
|
SCA
5
Sassicaia Capital Advisers
Jericho,
New York
| $1.7K | +$3.8K | +640 | New |
|
|
XT
6
XTX Topco
George Town,
Cayman Islands
| $1.28K | -$2.38K | -401 | -45% |
|
|
TSS
7
Two Sigma Securities
New York
| – | -$13.7K | -1,019 | Closed |
|
|
8
Two Sigma Investments
New York
| – | -$8.72K | -650 | Closed |
|
|
9
Morgan Stanley
New York
| – | -$1 | – | – |
|
PPCB Hedge Fund Activity: Q1 2026 in Review
6 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Propanc Biopharma (PPCB) for Q1 2026, worth a combined $48.7K — down 30% from $69.5K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PPCB positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $43.4K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $13.7K sold.
- 6 institutional investors held Propanc Biopharma (PPCB) as of Q1 2026, up from 4 in Q4 2025.
- Funds reported $48.7K of Propanc Biopharma stock for Q1 2026, down 30% quarter-over-quarter.
- 4 funds opened new Propanc Biopharma positions in Q1 2026 and 2 closed out, a net change of +2 holders.
- The largest Propanc Biopharma buyer in Q1 2026 was UBS Group, an estimated $43.4K added.
- The largest Propanc Biopharma seller in Q1 2026 was Two Sigma Securities, an estimated $13.7K sold.
Based on aggregated 13F filings for Q1 2026.